Long Washout Periods Between Biologics for Inflammatory Bowel Disease Clinical Trials Are Unnecessary: A Canadian Retrospective Cohort Study

INTRODUCTION: To assess the safety of early vs late biologic switch in patients with inflammatory bowel disease.METHODS: In this retrospective study, we included patients with inflammatory bowel disease who underwent biologic switch between January 2014 and July 2022 at a tertiary center. The primary outcome was any infection by 6 months.RESULTS: There was no statistically significant difference between patients who had early biologic switch (<= 30 days, n = 51) and late switch (>30 days, n = 77) in either infectious or noninfectious adverse events by 6 and 12 months.DISCUSSION: Early biologic switch is safe. A prolonged washout period between 2 biologics is unnecessary.